Journal of vascular surgeryOct 29, 2026

GLP-1 Receptor Agonists May Lower Rupture Risk, Heart Problems, and Death in Patients with Abdominal Aortic Aneurysms

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Nov 2, 2026

Abstract

The impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on patients with abdominal aortic aneurysm (AAA) is not well understood.

Abdominal aortic aneurysm involves inflammation, tissue remodeling, and potential ruptures.
GLP-1RA are effective in treating type 2 diabetes and may possess anti-inflammatory and cardiovascular benefits.
Current data on the relationship between GLP-1RA and AAA outcomes is limited.
The study aims to explore the association between GLP-1RA use and patient outcomes in AAA.

Simplified

Abdominal aortic aneurysm (AAA) is a degenerative condition involving several processes including inflammation, matrix remodeling, disruptions of vascular smooth muscle cells, and thrombus formation all leading to progressive dilatation of the aorta and eventual rupture. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are now considered part of the frontline therapeutic options to treat type 2 diabetes mellitus and have also been validated as having compelling anti-inflammatory and cardiovascular protective properties. Data is limited on the impact of GLP-1RA on outcomes of patients with AAA. The aim of this study is to examine the association and possible impact of GLP-1RA on patients with AAA.

Full Text

Full text is available at the source.

View Full Text ↗

GLP-1 Receptor Agonists May Lower Rupture Risk, Heart Problems, and Death in Patients with Abdominal Aortic Aneurysms

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief